Soleil Boughton Sells 2,637 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,637 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $58.79, for a total transaction of $155,029.23. Following the transaction, the insider directly owned 163,767 shares of the company’s stock, valued at $9,627,861.93. This trade represents a 1.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, September 17th, Soleil Boughton sold 2,637 shares of Hims & Hers Health stock. The shares were sold at an average price of $50.50, for a total transaction of $133,168.50.
• On Monday, August 25th, Soleil Boughton sold 2,571 shares of Hims & Hers Health stock. The shares were sold at an average price of $44.53, for a total transaction of $114,486.63.
• On Monday, August 11th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The shares were sold at an average price of $51.64, for a total transaction of $132,818.08.
• On Monday, July 28th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.70, for a total transaction of $150,976.40.
• On Monday, July 14th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The shares were sold at an average price of $47.82, for a total transaction of $122,993.04.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $56.27 on Thursday. The company’s fifty day simple moving average is $51.55 and its 200-day simple moving average is $46.86. Hims & Hers Health, Inc. has a 52 week low of $16.05 and a 52 week high of $72.98. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The company has a market cap of $12.72 billion, a PE ratio of 70.33, a P/E/G ratio of 3.83 and a beta of 2.25.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business had revenue of $544.83 million during the quarter, compared to analysts’ expectations of $550.06 million. During the same period in the prior year, the business posted $0.06 EPS. The business’s revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in HIMS. Invesco Ltd. grew its holdings in Hims & Hers Health by 502.2% during the 2nd quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock worth $127,237,000 after acquiring an additional 2,128,587 shares in the last quarter. Nuveen LLC acquired a new position in Hims & Hers Health during the 1st quarter worth $58,403,000. Clear Street LLC bought a new position in shares of Hims & Hers Health in the 2nd quarter worth about $83,582,000. Norges Bank bought a new position in shares of Hims & Hers Health in the 2nd quarter worth about $78,464,000. Finally, Marex Group plc bought a new position in shares of Hims & Hers Health in the 2nd quarter worth about $53,626,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on HIMS. UBS Group set a $30.00 price target on shares of Hims & Hers Health in a report on Monday, June 23rd. Canaccord Genuity Group reaffirmed a “buy” rating and set a $68.00 price target on shares of Hims & Hers Health in a report on Friday, September 12th. Zacks Research lowered shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Morgan Stanley reaffirmed an “equal weight” rating and set a $40.00 price target on shares of Hims & Hers Health in a report on Wednesday, June 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Two research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.